Brief: SciBase Holding: Nevisense To Be Included In Clinical Study At NYU Langone Health
18/08/2020 07:14
Aug 18 (Reuters) - SciBase Holding AB (publ) SCIB.ST :
* NEVISENSE SELECTED FOR `SPOTCHECK' REMOTE MELANOMA
DETECTION
EVALUATION STUDY BY THE RONALD O. PERELMAN DEPARTMENT OF
DERMATOLOGY AT NYU LANGONE HEALTH
* SPOTCHECK STUDY WILL INVESTIGATE USE OF NEVISENSE AS A
POINT-OF-CARE DIAGNOSTIC TOOL TO ASSIST WITH SKIN CANCER
DETECTION IN A REMOTE SETTING SUCH AS A NON-SPECIALIST PRACTICE
OR PHARMACY
* STUDY WILL EVALUATE HOW NEVISENSE CAN HELP PROVIDERS
ASSESS
PATIENTS' IRREGULAR MOLES IN SUCH LOCATIONS, AND IF SUCCESSFUL
WILL HELP IMPROVE ACCESS FOR PATIENTS TO TECHNOLOGY FOR EARLY
DETECTION OF MELANOMA
Source text for Eikon: ID:nWkr47QXXC
Further company coverage: SCIB.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))